46.71

0.06% 0.03

After Hours: 46.71

Springworks Therapeutics Inc (SWTX)

Overview News Price History Option Chain Financials Discussions Forecast

Springworks Therapeutics Inc stock is traded at $46.71, with a volume of 4.43M. It is up +0.06% in the last 24 hours and up +1.02% over the past month. SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

Previous Close:

$46.68

Open:

$46.68

24h Volume:

4.43M

Relative Volume:

0.94

Market Cap:

$3.52B

Revenue:

Net Income/Loss:

$-275.16M

P/E Ratio:

-12.01

EPS:

-3.89

Net Cash Flow:

$-221.15M

1W Performance:

+0.49%

1M Performance:

+1.02%

6M Performance:

+12.61%

1Y Performance:

+9.62%

1-Day Range:

$46.66

$46.75

1-Week Range:

$46.46

$46.77

52-Week Range:

$28.21

$62.00

Springworks Therapeutics Inc Stock (SWTX) Company Profile

Name

Springworks Therapeutics Inc

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

203-883-9490

Address

100 WASHINGTON BOULEVARD, STAMFORD, CT

Employee

368

Twitter

@springworkstx

Next Earnings Date

2024-11-12

Latest SEC Filings

SWTX's Discussions on Twitter

Compare SWTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SWTX Springworks Therapeutics Inc	46.71	3.50B	0	-275.16M	-221.15M	-3.89
ONC Beone Medicines Ltd Adr	245.58	26.10B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.96B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	42.96M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.39B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	63.52B	14.09B	4.50B	2.96B	39.28

Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-20-24	Initiated	Evercore ISI	Outperform
Feb-05-24	Initiated	Guggenheim	Buy
Dec-01-22	Initiated	BofA Securities	Buy
Jan-19-21	Reiterated	H.C. Wainwright	Buy
Oct-29-20	Reiterated	H.C. Wainwright	Buy
May-05-20	Initiated	Barclays	Overweight
Mar-19-20	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-04-20	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-21-20	Reiterated	H.C. Wainwright	Buy
Dec-04-19	Initiated	H.C. Wainwright	Buy
Oct-08-19	Initiated	Cowen	Outperform
Oct-08-19	Initiated	Goldman	Buy
Oct-08-19	Initiated	JP Morgan	Overweight
Oct-08-19	Initiated	Wedbush	Outperform

View All

Springworks Therapeutics Inc Stock (SWTX) Latest News

May 31, 2025

Nuveen Asset Management LLC Has $6.64 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 31, 2025

May 30, 2025

BNP Paribas Financial Markets Purchases Shares of 9,719 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 30, 2025

Promising Growth Stocks To Research – May 28th - Defense World

May 30, 2025

May 29, 2025

ProShare Advisors LLC Has $827,000 Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 29, 2025

May 28, 2025

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Recommendation of "Hold" by Analysts - MarketBeat

May 28, 2025

Deutsche Bank AG Purchases 19,540 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 28, 2025

Merck, SpringWorks receive German antitrust approval for their deal - MLex

May 28, 2025

SpringWorks Therapeutics (NASDAQ:SWTX) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat

May 28, 2025

Palisades Investment Partners LLC Purchases 12,154 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 28, 2025

May 27, 2025

Bank of America Corp DE Reduces Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 27, 2025

SpringWorks Therapeutics (SWTX) Surged on Acquisition News - Insider Monkey

May 27, 2025

BNP Paribas Financial Markets Makes New $351,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World

May 27, 2025

May 26, 2025

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease - Nasdaq

May 26, 2025

142,300 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Bought by Zimmer Partners LP - MarketBeat

May 26, 2025

May 25, 2025

SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges - Investing.com

May 25, 2025

SpringWorks Therapeutics receives positive CHMP opinion for Mirdametinib for the treatment of adult and paediatric patients with NF1-PN | Health & Wellbeing | Lifestyle - The Phoenix Newspaper UK

May 25, 2025

SpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume Increase – Time to Buy? - Defense World

May 25, 2025

Woodline Partners LP Raises Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 25, 2025

May 24, 2025

SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN - GlobeNewswire Inc.

May 24, 2025

Rafferty Asset Management LLC Has $4.44 Million Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 24, 2025

Velan Capital Investment Management LP Acquires Shares of 185,520 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 24, 2025

Tema Etfs LLC Takes $1.11 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 24, 2025

May 23, 2025

SpringWorks’ drug nears EU approval for neurofibromatosis treatment By Investing.com - Investing.com South Africa

May 23, 2025

SpringWorks Therapeutics (SWTX) Gains EMA Panel Support for Mird - GuruFocus

May 23, 2025

SpringWorks gets EU endorsement for genetic disorder treatment - Seeking Alpha

May 23, 2025

SpringWorks’ drug nears EU approval for neurofibromatosis treatment - Investing.com Australia

May 23, 2025

Springworks Therapeutics Says Mirdametinib Recommended by EU Panel for Treating Plexiform Neurofibromas - marketscreener.com

May 23, 2025

SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN - marketscreener.com

May 23, 2025

SpringWorks: CHMP Adopts Positive Opinion For Mirdametinib - Nasdaq

May 23, 2025

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN - The Manila Times

May 23, 2025

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mird - GuruFocus

May 23, 2025

SpringWorks Therapeutics (SWTX) Receives Positive Opinion from E - GuruFocus

May 23, 2025

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN | SWTX Stock News - GuruFocus

May 23, 2025

SpringWorks Therapeutics (SWTX) Receives Positive Opinion from EMA for Mirdametinib | SWTX Stock News - GuruFocus

May 23, 2025

SpringWorks Therapeutics Reports Positive CHMP Opinion for Mirdametinib as Potential First Therapy for NF1-PN in EU - Nasdaq

May 23, 2025